Ipravent

Ipratropium bromide, the active ingredient in Ipravent, is an anticholinergic bronchodilator presented as an inhalation solution for inhalation use. It provides bronchodilation to help manage chronic obstructive pulmonary disease, asthma and other bronchospastic conditions in adult patients.

GNH USA supplies Ipravent as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network adheres to stringent quality standards and regulatory requirements, ensuring reliable access to this essential respiratory medication across multiple regions. We partner with accredited logistics providers to maintain product integrity during transit.

Ipratropium bromide is used to treat respiratory conditions that involve airway constriction. - Chronic obstructive pulmonary disease (COPD): improves airflow and reduces breathlessness. - Asthma: provides additional bronchodilation when used with other controllers. - Bronchospasm: relieves acute narrowing of the airways during episodes.

Ipratropium bromide may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dry mouth: reduced salivary secretion. - Cough: irritation of the airway. - Throat irritation: mild soreness after inhalation.

Serious or Rare Side Effects: - Paradoxical bronchospasm: worsening airway constriction. - Allergic reaction: rash, itching, swelling. - Angioedema: rapid swelling of face or lips.

Before prescribing Ipratropium bromide, clinicians should consider several precautionary measures to ensure safe use. - Assess respiratory status: confirm diagnosis of COPD, asthma or bronchospasm. - Review concomitant anticholinergics: avoid additive anticholinergic burden. - Monitor for urinary retention: especially in patients with prostate enlargement. - Caution in patients with narrow-angle glaucoma: may exacerbate intra‑ocular pressure. - Adjust use in renal impairment: dose may need modification in severe renal failure. - Store at room temperature: keep below 25 °C, protect from moisture and direct sunlight.

Ipratropium bromide can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Combined use with other anticholinergics (e.g., tiotropium): may increase anticholinergic side effects. - Concurrent high‑dose beta‑agonists: risk of cardiovascular stimulation.

Moderate Interactions (Monitor Closely): - Inhaled corticosteroids: may increase risk of oral thrush, monitor oral hygiene. - Ophthalmic anticholinergics: watch for additive glaucoma risk. - Certain antihistamines: may enhance dry mouth, advise patient hydration.